ReNAgade is acquired by RNA rival a year after megaround-backed launch

Ryan Cross

Senior Science Correspondent

Two buzzy, well-funded biotech startups are combining in a bid to create a powerhouse at the bleeding edge of genetic medicines.
Orna Therapeutics announced Thursday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ReNAgade is acquired by RNA rival a year after megaround-backed launch

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Rare pediatric disease vouchers face uncertain future after September

Gilead cancer drug magrolimab showed worrying trends around death

AI drug discovery startup goes public in Hong Kong, nabbing $115M to build on pharma partnerships

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

De-risking the patient journey in cell therapies: Six key considerations

Re­NA­gade is ac­quired by RNA ri­val a year af­ter megaround-backed launch

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

AI drug dis­cov­ery start­up goes pub­lic in Hong Kong, nab­bing $115M to build on phar­ma part­ner­ships

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

ReNAgade is acquired by RNA rival a year after megaround-backed launch

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Rare pediatric disease vouchers face uncertain future after September

Gilead cancer drug magrolimab showed worrying trends around death

AI drug discovery startup goes public in Hong Kong, nabbing $115M to build on pharma partnerships

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

De-risking the patient journey in cell therapies: Six key considerations